← Back to Search

Community-Based, Client-Centered Prevention Home for Opioid Use Disorder

Phase 3
Waitlist Available
Led By Ryan Westergaard, MD, PhD, MPH
Research Sponsored by University of Wisconsin, Madison
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up year 2
Awards & highlights

Study Summary

This trial will test if a 12-week intensive multilevel harm reduction case-management intervention can help reduce risky behaviors and lower infectious disease risks in people who inject drugs.

Eligible Conditions
  • Opioid Use Disorder
  • Substance Use Disorder
  • Self-Harm
  • Hepatitis C

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~year 2
This trial's timeline: 3 weeks for screening, Varies for treatment, and year 2 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Social stigmata
Change in smoking frequency as assessed by self-reported behaviors
Change in the addiction treatment accessibility and utilization as assessed by change in Likert scale
+5 more
Secondary outcome measures
Narcan
Change in the treatment frequency of viral hepatitis as assessed by Wisconsin(WI) surveillance databases and Medicaid data.
Other outcome measures
Addiction treatment accessibility and utilization frequency assessment from long term Medicaid data.
Hepatitis C treatment frequency from long term Medicaid data.

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: Immediate InterventionExperimental Treatment1 Intervention
Participants enrolled in this arm will receive a 12-week community-based, client-centered, prevention intervention.
Group II: Delayed InterventionExperimental Treatment1 Intervention
Participants enrolled in this arm will receive a 12-week community-based, client-centered, prevention intervention after being put on a wait-list for three months. Per the protocol amendment approved on 9/3/2021, no additional participants will be recruited into the delayed intervention arm.
Group III: NoninterventionActive Control1 Intervention
Participants enrolled in this arm will receive services as usual from Vivent Health and will not engage in the intervention.

Find a Location

Who is running the clinical trial?

University of Wisconsin, MadisonLead Sponsor
1,176 Previous Clinical Trials
3,011,665 Total Patients Enrolled
Tulane UniversityOTHER
115 Previous Clinical Trials
226,161 Total Patients Enrolled
National Institute on Drug Abuse (NIDA)NIH
2,447 Previous Clinical Trials
2,593,725 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many people are being offered the chance to participate in this clinical trial?

"That is correct. The latest information from clinicaltrials.gov shows that this trial, which was first advertised on March 12th 2020, is still recruiting patients. The aim is to have 405 people enrolled from 7 different hospitals or clinics."

Answered by AI

What are some dangers associated with the Community-Based, Client-Centered Prevention Home?

"There is some evidence of this intervention's efficacy, as well as multiple rounds of data affirming its safety, so it was given a 3."

Answered by AI
~68 spots leftby Mar 2025